ClinicalTrials.gg
Active, not recruitingNCT03104517CELLEBRATEUpdated Oct 21, 2026

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

A Phase 3 interventional study of AMDC-USR (iltamiocel) and Placebo in Stress Urinary Incontinence, sponsored by Cook MyoSite. Active, not recruiting at 21 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Cook MyoSite (part of Cook Group Incorporated) · Phase 3, Interventional, and Treatment

How we know

Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.

Planned enrollment
84th of 164
96 · median 99
Started
2019
with 16 others
Phase 3
21 of 190
2 open now
Primary completion
2026-06
later than 12 of 40 live
Registered
86th of 190
by date
Lead sponsor
5 of 190
Cook MyoSite

Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 84th largest by planned enrollment of the 164 interventional ones that give a count, is one of 17 that started in 2019, is one of 21 in phase 3, reaches primary completion later than 12 of the 40 other live ones, and was the 86th registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the efficacy and safety of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) compared to a placebo in the reduction of stress incontinence episode frequency in adult female patients with post-surgical persistent or recurrent stress urinary incontinence (SUI). Half of the participants will receive AMDC-USR (injections with cells) and the other half will receive placebo.

Read the detailed description

Stress urinary incontinence (SUI) is the accidental loss of urine due to physical activity, such as laughing, coughing, or sneezing. Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR; generic name: iltamiocel) involves a medical procedure in which a participant's own muscle cells are collected, processed, and then injected into the tissues of the urinary passage.

This is a double-blind randomized study, which means neither the participant, nor the study doctor will know which treatment group the participant will be in. Participants who are randomly chosen to receive injection with placebo will have the option to receive an injection with their cells after completion of the blinded portion of their study participation (12 months).

03

Conditions studied

  • Stress Urinary Incontinence

Keywords

  • Urinary Incontinence
  • Urinary Stress Incontinence
  • Lower Urinary Tract Symptoms
  • Urinary Bladder
  • Urinary Tract Diseases
  • Bladder
  • Urinary Leak
  • Urine Leak
  • Bladder Leak
  • Urethra
  • Urethral Sphincter
  • Persistent Incontinence
  • Recurrent Incontinence
  • Incontinence Surgery
  • Sling Surgery
  • Stress Urinary Incontinence Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult female patient ≥ 18 years of age who has primary and moderate-to-severe symptoms of SUI for at least 6 months, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation.
  • History of previous surgery for treatment of SUI. Previous surgery could include midurethral sling, retropubic suspension, or bladder neck sling. Bulking agents alone are not considered previous surgery for treatment of SUI.
  • Must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the form prior to any study-related procedures.
  • Must have completed 100% of the screening 3-day diary evening reports.

Exclusion criteria

Exclusion Criteria:

  • Patient has symptoms of only urge incontinence as confirmed by basic evaluation of etiology from a patient medical history, including a focused incontinence history.
  • Patient has symptoms of mixed urinary incontinence where urge incontinence is the predominant factor.
  • Patient has had stress urinary incontinence symptoms less than 6 months prior to signing the .
  • Patient has not previously attempted conservative treatment prior to signing the informed consent. (Examples of conservative treatment include behavior modifications, bladder exercises, biofeedback, pelvic floor muscle therapy, etc.)
  • Patient ≥ 35.
  • Patient routinely has more than 2 episodes of awakening to void during normal sleeping hours.
  • If taking a medication known to affect lower urinary tract function, including but not limited to, anticholinergics, beta 3 adrenergic receptor agonists, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants, diuretics, or alpha-adrenergic blockers, patient cannot be maintained on a stable dose and/or frequency of medication (including diuretics), cannot be maintained on a stable dose and/or frequency for at least 2 weeks prior to screening or is likely to change during the course of the study.
  • History of cancer in pelvic organs, ureters, or kidneys.
  • Patient is pregnant, lactating, or plans to become pregnant during the course of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    AMDC-USR (iltamiocel)

    Autologous muscle-derived cells for urinary sphincter repair (AMDC-USR; generic name: iltamiocel) is the study product.

    Biological: AMDC-USR (iltamiocel)

  • Placebo comparator
    Placebo

    Placebo control is the vehicle solution used for the study product.

    Other: Placebo

Interventions

  • BiologicalIltamiocelStudies of IltamiocelIltamiocel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)

  • OtherPlacebo

    Placebo control is the vehicle solution used for the study product.

06

What researchers measure

Primary outcomes

  1. Number of leaks due to stress incontinence episodes, as recorded in a diary

    Stress leak frequency

    Time frame: 12 months

07

Study locations

21 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jun 2026, 85 months.

Of 14 phase 3 interventional studies under Urinary Incontinence, Stress, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's 85 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Sep 2026 → Jun 2026 and completion Sep 2027 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2017
First posted
Apr 7, 2017
StartActual
Apr 23, 2019
Primary completionActual
Jun 11, 2026was Sep 2026
CompletionEst.
Nov 2026was Sep 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jun 11, 2026 (actual)
Oct 21, 2026
Study completion
Sep 2027→Nov 2026
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Sep 2026→Jun 11, 2026 (now actual)
    Study completion Sep 2027→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03104517
Lead sponsor
Cook MyoSite
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Apr 23, 2019
Primary completion
Jun 11, 2026
Completion
Nov 2026 (estimated)
Last update
Oct 21, 2026

Study contacts

Melissa Kaufman, M.D., Ph.D.
principal investigator · Vanderbilt University Medical Center, Department of Urologic Surgery

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iltamiocel

Start the discussion